Searched for:
(1 - 12 of 12)
document
Eefting, D. (author), Seghers, L. (author), Grimbergen, J.M. (author), de Vries, M.R. (author), de Boer, H.C. (author), Lardenoye, J.W.H.P. (author), Jukema, J.W. (author), van Bockel, J.H. (author), Quax, P.H.A. (author), TNO Kwaliteit van Leven (author)
Aims Matrix metalloproteinases (MMP) and plasminogen activator (PA)/plasmin-mediated proteolysis, especially at the cell surface, play important roles in matrix degeneration and smooth muscle cell migration, which largely contributes to vein graft failure. In this study, a novel hybrid protein was designed to inhibit both protease systems...
article 2010
document
van der Hoeven, B.L. (author), Pires, N.M.M. (author), Warda, H.M. (author), Putter, H. (author), Quax, P.H.A. (author), Schalij, M.J. (author), Jukema, J.W. (author), TNO Kwaliteit van Leven (author)
Diabetes mellitus (DM) is a strong predictor of in-stent restenosis. This may be due to a higher level of vascular inflammation. We hypothesized that diabetic patients will benefit from dexamethasone-eluting stents, since local inflammation and consequently neointimal growth are suppressed and no systemic side effects will occur. Methods: 21...
article 2008
document
Kupreishvili, K. (author), ter Weeme, M. (author), Morré, S.A. (author), van den Brule, A.J.C. (author), Huybregts, M.A.J.M. (author), Quax, P.H.A. (author), ten Velden, J. (author), van Hinsbergh, V.W.M. (author), Stooker, W. (author), Eijsman, L. (author), Niessen, H.W.M. (author), TNO Kwaliteit van Leven (author)
Background: Several studies have suggested an association between Chlamydophila pneumoniae (Cp) infection and atherosclerosis. A recent study detected Cp DNA in the saphenous vein of 12% of all patients before bypass grafting and in 38% of failed grafts. We used a system in which human veins were perfused with autologous blood under arterial...
article 2008
document
van Weel, V. (author), van Tongeren, R.B. (author), van Hinsbergh, V.W.M. (author), van Bockel, J.H. (author), Quax, P.H.A. (author), TNO Kwaliteit van Leven (author)
Stimulation of vascular growth to treat limb ischemia is promising, and early results obtained from uncontrolled clinical trials using angiogenic agents, e.g., vascular endothelial growth factor, led to high expectations. However, negative results from recent placebo-controlled trials warrant further research. Here, current insights into...
article 2008
document
Monraats, P.S. (author), Kurreeman, F.A.S. (author), Pons, D. (author), Sewgobind, V.D.K.D. (author), de Vries, F.R. (author), Zwinderman, A.H. (author), de Maat, M.P.M. (author), Doevendans, P.A. (author), de Winter, R.J. (author), Tio, R.A. (author), Waltenberger, J. (author), Huizinga, T.W.J. (author), Eefting, D. (author), Quax, P.H.A. (author), Frants, R.R. (author), van der Laarse, A. (author), van der Wall, E.E. (author), Jukema, J.W. (author), TNO Kwaliteit van Leven (author)
Genetic factors appear to be important in the process of restenosis after percutaneous coronary intervention (PCI), as well as in inflammation, a pivotal factor in restenosis. An important mediator in the inflammatory response is interleukin (IL)-10. Our aim was to study whether genetic variants in IL-10 predispose to the risk of restenosis. The...
article 2007
document
Pires, N.M.M. (author), Jukema, J.W. (author), Daemen, M.J.A.P. (author), Quax, P.H.A. (author), TNO Kwaliteit van Leven (author)
In 2001, the first human study with drug-eluting stents (DES) was published showing a nearly complete abolition of restenosis by using a sirolimus-eluting stent. This success was very encouraging to test new compounds in combination with the DES platform. Nevertheless, several other anti-restenotic compounds have been used in human clinical...
article 2006
document
van der Laan, W.H. (author), Pap, T. (author), Ronday, H.K. (author), Grimbergen, J.M. (author), Huisman, L.G.M. (author), TeKoppele, J.M. (author), Breedveld, F.C. (author), Gay, R.E. (author), Gay, S. (author), Huizinga, T.W.J. (author), Verheijen, J.H. (author), Quax, P.H.A. (author)
article 2000
document
Quax, P.H.A. (author), Grimbergen, J.M. (author), Lansink, M. (author), Bakker, A.H.F. (author), Blatter, M.C. (author), Belin, D. (author), van Hinsbergh, V.W.M. (author), Verheijen, J.H. (author), Gaubius Instituut TNO (author)
Urokinase-type plasminogen activator (UPA), particularly when bound to its receptor (UPAR), is thought to play a major role in local proteolytic processes, thus facilitating cell migration as may occur during angiogenesis, neointima and atherosclerotic plaque formation, and tumor cell invasion. To facilitate understanding of the need and...
article 1998
document
Ronday, H.K. (author), Smits, H.H. (author), Quax, P.H.A. (author), van der Pluijm, G. (author), Löwik, C.W.G.M. (author), Breedveld, F.C. (author), Verheijen, J.H. (author), Gaubius Instituut TNO (author)
article 1995
document
de Bart, A.C.W. (author), Quax, P.H.A. (author), Löwik, C.W.G.M. (author), Verheijen, J.H. (author), TNO Preventie en Gezondheid (author)
Plasmin-mediated extracellular proteolysis has been implicated in the degradation of bone in normal and pathological conditions. Normal and malignant osteoblasts can produce both tissue-type plasminogen activator (t- PA) and urokinase-type plasminogen activator (u-PA). We have used the osteosarcoma cell line MG63 to address the question of...
article 1995
document
van Hinsbergh, V.W.M. (author), Quax, P.H.A. (author), Koolwijk, P. (author), Verheijen, J.H. (author), TNO Preventie en Gezondheid (author)
Abstract
article 1994
document
Weening-Verhoeff, E.J.D. (author), Quax, P.H.A. (author), van Leeuwen, R.T.J. (author), Rehberg, E.F. (author), Marotti, K.R. (author), Verheijen, J.H. (author), Gaubius Instituut TNO (author)
article 1990
Searched for:
(1 - 12 of 12)